Multiple sclerosis activated by anti-tumor necrosis factor α (Etanercept) and the genetic risk
Neurol India
.
2016 Sep-Oct;64(5):1042-4.
doi: 10.4103/0028-3886.190240.
Authors
Edvina Galiè
1
,
Bruno Jandolo
1
,
Alyne Martayane
2
,
Rosaria Renna
3
,
Tatiana Koudriavtseva
4
Affiliations
1
Division of Neurology, Regina Elena National Cancer Institute, IFO, Rome, Italy.
2
Division of Clinical Pathology, Regina Elena National Cancer Institute, IFO, Rome, Italy.
3
Division of Neurology, Regina Elena National Cancer Institute, IFO; Institute of Neurology, Catholic University of Sacred Heart, Rome, Italy.
4
Division of Neurology, Regina Elena National Cancer Institute, IFO; Department of Systems Medicine, Tor Vergata University, Rome, Italy.
PMID:
27625254
DOI:
10.4103/0028-3886.190240
No abstract available
Publication types
Case Reports
Letter
MeSH terms
Antibodies, Monoclonal / adverse effects*
Etanercept / adverse effects*
Humans
Multiple Sclerosis / chemically induced*
Risk Factors
Substances
Antibodies, Monoclonal
Etanercept